Skip navigation
Watchlist Sponsored By :

As of Friday, November 27th:
The blended earnings growth rate for the S&P 500 for Q3 2009, combining actual numbers for companies that have reported, and estimates for companies yet to report is currently -13.7%. Of the 490 S&P 500 companies who have reported Q3, 79% beat estimates, 7% were in-line, and 14% were below estimates. As of October 1st, the earnings growth rate was at -24.7%. (Data provided by Thomson Reuters)

LATEST EARNINGS RESULTS


Current DateTime: 04:50:32 29 Nov 2009
LinksList Documentid: 29017166
Expiration DateTime: 11/29/2009 4:51:26 AM

Current DateTime: 04:50:33 29 Nov 2009
LinksList Documentid: 24355697
  • Runway Angels

      The superbowl of fashion shows, models walk down the runway at the 2009 Victoria's Secret Show.

  • Smartphone Guide

      Here's a need-to-know guide to nine devices, based on features, price, network and platform.

  • Wines for the Holidays

      Not quite sure what wine to pair with Turkey or Creme Brulee? Our experts do.

FEATURED QUIZZES


Current DateTime: 04:50:33 29 Nov 2009
LinksList Documentid: 33793611
  • How Well Do You Know Your Bird?

      Let's talk turkey. Test your turkey knowledge and perhaps pick up a bit of trivia to trot out at your holiday meal.

  • A Healthier & Wealthier You

      Take the following quiz and find out how much you know about the impact of obesity on the health of the U.S. economy.

  • The Billionaire BFF's

      Philanthropists. Bridge partners. Hockey players. Which responses are based on facts from Buffett's and Gates' real lives?


Current DateTime: 04:50:33 29 Nov 2009
LinksList Documentid: 24890560
  • Winterizing Your Portfolio

      If 2009 was the winter of our discontent, will 2010 be a winter wonderland for investors? A lot depends on the recovery—or lack thereof.

  • Investor's Guide to Real Estate

      Some even say the long-awaited recovery is here. Regardless, buyers and sellers alike can profit from our guide.

  • Alternative Investing

      Stocks and bonds? Sure. But it's a big world out there for investors.

powered by digg
Merck Misrepresented Vioxx Data: JAMA Report
By: Mike Huckman,, Pharmaceuticals Reporter | 15 Apr 2008 | 03:47 PM ET
Text Size

A new report in the Journal of the American Medical Association is highly critical of drugmaker Merck and its handling of the painkiller Vioxx.

The JAMA article says Merck [MRK  Loading...      ()   ] misrepresented apparent Vioxx-related deaths in studies to see if the drug worked on Alzheimer's Disease.

A review of the clinical trials, which came to light during the Vioxx litigation, shows a three-fold increase in the risk of death among the patients who got Vioxx, according to the peer-reviewed medical journal.

But in a press release, Merck says that after careful analysis there was no suggestion the deaths were caused by the drug and that the JAMA report's conclusions are "false, misleading, or lack context".

Merck voluntarily pulled Vioxx off the market in 2004 because of an increased heart risk.  The company has since settled most of the resulting lawsuits for nearly $5 billion.

One of the two authors of the JAMA article was a paid expert witness for Vioxx plaintiffs.

© 2009 CNBC.com
Tools:
Print EmailAdd This share icon

Current DateTime: 04:50:33 29 Nov 2009
LinksList Documentid: 29016957
Expiration DateTime: 11/29/2009 4:51:57 AM

Current DateTime: 04:50:33 29 Nov 2009
LinksList Documentid: 29017287
Expiration DateTime: 11/29/2009 4:51:27 AM


Current DateTime: 01:04:03 29 Nov 2009
LinksList Documentid: 29778428

Current DateTime: 01:04:03 29 Nov 2009
LinksList Documentid: 29779196

Current DateTime: 01:00:33 29 Nov 2009
LinksList Documentid: 29779199

Current DateTime: 01:04:03 29 Nov 2009
LinksList Documentid: 29779198
  Data is a real-time snapshot  *Data is delayed at least 15 minutes
Global Business and Financial News, Stock Quotes, and Market Data and Analysis

© 2009 CNBC, Inc.  All Rights Reserved.
A Division of NBC Universal
Thomson ReutersThomson Reuters